Elpis Biopharmaceuticals Collaborates with Singapore General Hospital to Advance Next-Generation CAR-T Therapies for Blood Cancers

LEXINGTON, Mass. & SINGAPORE – June 4, 2025 – Elpis Biopharmaceuticals, a clinical-stage cell therapy company focused on bispecific armored CAR-T therapies for solid tumors, has entered into a research collaboration agreement with Singapore General Hospital (SGH). This partnership will focus on developing next-generation allogeneic CAR technologies, including an armored CAR-γδT (gamma-delta-T) targeting acute myeloid leukemia (AML) and a bispecific CAR-γδT for multiple myeloma (MM).

Under the agreement, Elpis has transferred its bispecific and armored CAR technologies to SGH. SGH will leverage its unique γδT platform and clinical expertise to advance these assets into separate investigator-initiated trials. If the data is favorable, both parties intend to explore forming a joint venture for further development and commercialization of the therapies.

Assistant Professor Alice Cheung, Junior Principal Investigator, Department of Haematology at SGH, highlighted, “CAR-γδTs represent the cutting edge of cancer therapy given the potential of such technologies to span the entirety of the immune system.” Assistant Professor Chen Yunxin, Senior Consultant, Department of Haematology at SGH, added, “Through our research collaboration with Elpis, we aim to develop potent and durable cell therapies for AML and MM. By leveraging robust immune modulation, our goal is to enhance antitumor activity and ultimately improve clinical outcomes.”

Elpis Biopharmaceuticals has developed a suite of proprietary technologies designed to overcome key challenges in tumor treatment, such as immune suppression within the tumor microenvironment (TME) and antigen heterogeneity. Their precision-engineered, cell-type-specific armor modulates the persistence of CAR-engineered immune cells and bystander immune cell activities.

Dr. Yan Chen, founder and CEO of Elpis Biopharmaceuticals, stated, “At Elpis, we are taking CAR-γδTs to the ‘next generation’ by combining cell type-specific multi-mechanism armor and bispecific tumor targeting antibodies.” He noted that these innovations are designed for safer, more effective, and persistent therapies at a significantly reduced cost compared to autologous CAR-Ts. Dr. Chen expressed excitement about aligning with SGH to initiate clinical trials for these AML and multiple myeloma therapies.